

**Public Declaration of Interests
The European Patients' Forum
Board Members**

Public Declaration of Interests

I,

Name: Stanimir Hasardzhiev

Organisation: National Patients' Organization

Country: Bulgaria

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in healthcare industries are those listed below:

Please indication N/A (Not applicable) as appropriate

2.1 Employment in the healthcare industry

Period	Company	Job title
N/A	N/A	N/A

2.2 Consultancy

- Consultancy to a company shall mean: any activity where the board member provides advice (including training on a one to one basis) to a company regardless of contractual arrangements or any form of remuneration.

Period	Company	Subject Matter

2.3. Consultancy/advisory role on patient-related activities in the last year

- The board member provides advice or participates in consultations regarding patient-related activities of a company that are strictly non-commercial (e.g. educational seminars, preparation and participation in patient meetings/trainings, development of non-product patient specific materials, participation in trainings of a company staff on patient-centricity etc.)

Period	Company	Subject Matter
3.02.2016	Gilead Sciences, Inc.	Presentation on “Working to secure access in HCV therapy” and exploring case study learnings during a group discussion
Feb 2016 – Mar 2016	Novartis Pharma Services	Advisory Board on preparation of EU CHRONIC DISEASES PATIENT SUMMIT in October 2016
2.03.2016	Astra Zeneca	Presentation during the International Forum on Personalized Medicine
19.07.2016	Medtronic	Presentation on How to assure access for the patients to personalized therapy across Europe
12.08.2016	Gilead Sciences Europe	Preparation and attendance at Policy and Practice Webinar series
17.11.2016	Novartis Pharma Services	Chairing and moderating a meeting of the CEE Think Tank on Patient Access
18.11.2016	Amgen	Moderation of the discussion at the American Society of Hematology Annual Meeting 2016

2.3 Strategic Advisory Role

Strategic advisory role for a company shall mean: any activity where the board members participating (with a right to vote/influence the outputs) in a(n) (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the (future) strategy, direction and development activities of a healthcare company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration.

Period	Company	Product	Therapeutic Indication
N/A	N/A	N/A	N/A

2.4 Financial Interests

Period	Company	Subject Matter
N/A	N/A	N/A

2.5 Principal Investigator

Period	Company	Subject Matter
N/A	N/A	N/A

2.6 Investigator

Period	Company	Subject Matter
N/A	N/A	N/A

2.7 Grant / Funding to Organisation /Institution in 2016 (This is the organisation which nominated you to become a member of EPF)

Company	Subject Matter and amount
Novartis	Project financing, 60 000 BGN
Gedeon Richter	Project financing, 10 000 BGN
Pier Fabre	Unrestricted grant, 5 000 BGN
Baxter	Unrestricted grant, 10 000 BGN
Astra Zeneca	Project financing, 5 000 BGN
ARPharM	Project financing, 10 000 BGN
Alcon	Unrestricted grant, 4 000 BGN
Astra Zeneca	Project financing, 3 000 BGN
GlaxoSmith Kline	Project financing, 20 200 BGN
Merck	Project financing, 24 250 BGN
Pfizer	Project financing, 70 000 BGN
Sanofi	Project financing, 10 000 BGN
Abbvie	Project financing, 10 000 BGN
MSD	Project financing, 8 000 BGN
Glaxo Smith Kline	Project financing, 17 500 BGN
NOVO NORDISK PHARMA	Project financing, 5 000 BGN

PIERRE FABRE	Project financing, 24 265 BGN
Alcon	Project financing, 15 065 BGN
ASTELLAS PHARMA	Project financing, 14 000 BGN
Glaxo Smith Kline	Project Financing, 25 000 BGN
ASTELLAS PHARMA	Project financing, 5867,49 BGN
Abbvie	Project financing, 9779,15 BGN
Pfizer	Unrestricted grant, 30 000 BGN
Pfizer	Project financing, 30 000 BGN
NOVO NORDISK	Project financing, 15 000 BGN
MSD	Project financing, 5 000 BGN
MSD	Project financing, 7 000 BGN
Amgen	Project financing, 10 000 BGN
Amgen	Project financing, 10 000 BGN
Amgen	Project financing, 15 000 BGN
Pfizer	Project financing, 19 558 BGN
Merck	Project financing, 48 800 BGN
Roche	Project financing, 58 560 BGN
MSD	Project financing, 30 000 €
Gilead	Project financing, 30 000 €
J&J	Project financing, 15 000 €
Mylan	Project financing, 5 000 €
Sanofi	Project financing, 10 000 €

2.8 Close Family Member Interest

Period	Company	Interest
N/A	N/A	N/A

2.9 Any Other Interests or Facts

N/A

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EPF website.

Full Name	Stanimir Hasardzhiev
Date	13.03.2017